04:57 PM EDT, 09/06/2024 (MT Newswires) -- Spyre Therapeutics ( SYRE ) on Friday filed a registration statement for the sale of up to $500 million of its securities from time to time in one or more offerings.

The filing covers the offering of common and preferred stock, debt securities, warrants and units.

The company said it plans to use the net proceeds to fund its clinical programs and general infrastructure development, and acquire or invest in additional businesses.